NDA 019992 · Sandoz
Ciloxan
Ciprofloxacin Hydrochloride · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Dec 31, 1990
Approved uses
2
Original approval plus efficacy supplements
Registered trials
364
90 Phase 3, 32 recruiting
FAERS reports
6,204
5,373 serious, 523 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 5, 2026.
INDICATIONS AND USAGE Ciprofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 27, 1994 Supplement 4 · Efficacy
- Dec 31, 1990 Original approval · Type 3 - New Dosage Form Pediatric Medical Review
1 products under this application
- CILOXAN · CIPROFLOXACIN HYDROCHLORIDE EQ 0.3% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/SulfamethoxazolePivotal-lookingStatus unknown
Umeå UniversityAcademic, hospital or other
NCT02734732 · 2,800 participants (planned) · Start Apr 2015 · Primary completion Apr 2020
Drug: Trimethoprim/Sulfamethoxazole; Ciprofloxacin · For: Prostate Infection
Sites: Östersund, Sweden; Sundsvall, Sweden; Ängelholm, Sweden · 5 sites in all
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00014222 · 2,104 participants · Start Dec 4, 2000 · Primary completion Feb 10, 2014
Drug: epoetin alfa; filgrastim and 5 more · For: Breast Cancer
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; La Jolla, California · 78 sites in all
University of WashingtonAcademic, hospital or other
NCT05286931 · 1,800 participants (planned) · Start Mar 3, 2022 · Primary completion Dec 31, 2025
Drug: Ciprofloxacin 500 mg · For: Neisseria Gonorrhoeae Infection
Sites: Seattle, Washington
- Antibiotic Prophylaxis Before Shock Wave LithotripsyPivotal-lookingCompleted
Clinical Urology and Epidemiology Working GroupGovernment (non-federal)
NCT03692715 · 1,732 participants · Start Sep 27, 2018 · Primary completion Dec 31, 2024
Drug: Ciprofloxacin; Placebo · For: Ureteral Stones; Ureteral Calculi; Nephrolithiasis
Sites: São Paulo, Brazil; London, Canada; Sherbrooke, Canada · 10 sites in all
- Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult WomenPivotal-lookingCompleted
Iterum Therapeutics, International LimitedIndustry
NCT03354598 · 1,671 participants · Start Aug 1, 2018 · Primary completion Jan 16, 2020
Drug: Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin · For: Uncomplicated Urinary Tract Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Tolleson, Arizona · 60 sites in all
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.Pivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT03228108 · 1,538 participants · Start Apr 3, 2018 · Primary completion Sep 26, 2021
Drug: Ciprofloxacin; Trimethoprim/Sulfamethoxazole and 2 more · For: Complication; Infection; Prostate Cancer
Sites: 's-Hertogenbosch, Netherlands; Arnhem, Netherlands; Bergen op Zoom, Netherlands · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting752
- pneumonia707
- dyspnoea698
- off label use668
- pain654
- nausea641
- drug hypersensitivity637
- malaise592
- diarrhoea587
- drug ineffective543
- fatigue533
- wheezing522
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 67 |
| 2006 | 63 |
| 2007 | 66 |
| 2008 | 89 |
| 2009 | 163 |
| 2010 | 80 |
| 2011 | 119 |
| 2012 | 298 |
| 2013 | 72 |
| 2014 | 81 |
| 2015 | 108 |
| 2016 | 132 |
| 2017 | 141 |
| 2018 | 275 |
| 2019 | 501 |
| 2020 | 417 |
| 2021 | 477 |
| 2022 | 603 |
| 2023 | 612 |
| 2024 | 676 |
| 2025 | 679 |
| 2026 | 441 |
Recalls
1 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ciloxan (Ciprofloxacin HCl)
2024 spending
$1.5M
Beneficiaries
3,881
5,419 claims
Per beneficiary
$391
$75.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $445,517 |
| 2022 | $1,277,565 |
| 2023 | $1,460,940 |
| 2024 | $1,517,511 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.
Randremanana RV, Raberahona M, Bourner J, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.
Hadidi MF, Alhamami N, Alhakami M, et al. · World J Urol 2024 · Systematic Review, Network Meta-Analysis
- Fluoroquinolones for treating tuberculosis.
Ziganshina LE, Vizel AA, Squire SB · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Fluoroquinolones for treating tuberculosis.
Ziganshina LE, Squire SB · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.
Dunne MW, Aronin SI, Das AF, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Antibiotics for preventing meningococcal infections.
Fraser A, Gafter-Gvili A, Paul M, et al. · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.